A large registry study identifies the ideal definition of progression independent of relapse activity, balancing sensitivity and specificity.
Progression independent of relapse activity (PIRA) is a major contributor to long-term disability in relapsing-remitting multiple sclerosis (RRMS), but inconsistent definitions hinder comparability across studies and adoption by therapeutic regulators. This retrospective cohort study included 33,303 patients with RRMS from the global MSBase registry (2004–2023), testing 360 combinations of PIRA definitions based on variations in baseline setting, disability-progression confirmation period, relapse exclusion windows, and disability-progression thresholds.
PIRA incidence varied widely (0.141–0.658 events per decade), and persistence (no disability improvement over 5 years) ranged from 75% to 92%, depending on the definition. The most-balanced …
Reviewing Author
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)